U.S. FDA Grants Accelerated Approval to Bayer’s Hyrnuo (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

Sep 11, 2026 - 10:00
 0  0
WHIPPANY, N.J., September 9, 2026 – Bayer announced today that following Priority Review and Breakthrough Therapy Designation, the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hyrnuo® (sevabertinib), for the...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0